Raymond A. Rubin - Concepedia

Author

Raymond A. Rubin

Cornell University ORCID

Also Known As

R A Rubin, R Rubin, R. Rubin, R.A. Rubin, Raymond A Rubin, Raymond A. Rubin, Raymond Rubin, Rubin, R, Sergio Rojter

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

Cornell University Hospital of the University of Pennsylvania Indiana University – Purdue University Indianapolis Baylor College of Medicine Indiana University School of Medicine

About

Raymond A. Rubin is an author at Cornell University specializing in medicine, hepatitis, and hepatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	3.2K
2	Health Sciences	5	6	948
3	Gastroenterology	2	2	88
4	Emergency Medicine	1	1	74
5	Epidemiology	1	1	45

Raymond A. Rubin

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Paul Y. Kwo, Eric Lawitz, Jonathan McCone, The Lancet HepatologyHepatitis CViral HepatitisNs3 Protease InhibitorAntiviral Drug Development	2010	703
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome Florence Wong, S. Chris Pappas, Michael P. Curry, New England Journal of Medicine	2021	421
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao, Gastroenterology	2019	326
Liver disease and diabetes mellitus. Baig Na, Steven K. Herrine, Raymond A. Rubin PubMed	2001	298
Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV Mark Sulkowski, Kenneth E. Sherman, Douglas T. Dieterich, Annals of Internal Medicine	2013	199
Intestinal varices: treatment with the transjugular intrahepatic portosystemic shunt. Ziv J. Haskal, Mark D. Scott, Raymond A. Rubin, Radiology	1994	108
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo Catherine Frenette, Giuseppe Morelli, Mitchell L. Shiffman, Clinical Gastroenterology and Hepatology	2018	97
4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C Paul Y. Kwo, E. Läwitz, Jonathan McCone, Journal of Hepatology A Phase 2Viral PersistenceHepatologyHepatitis CSvr 24	2009	86

Page 1